Last reviewed · How we verify

Vi-TT — Competitive Intelligence Brief

Vi-TT (Vi-TT) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Typhoid conjugate vaccine. Area: Immunology / Infectious Disease.

marketed Typhoid conjugate vaccine Salmonella typhi Vi polysaccharide antigen Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Vi-TT (Vi-TT) — International Vaccine Institute. Vi-TT is a typhoid conjugate vaccine that stimulates immune responses against Salmonella typhi by presenting the polysaccharide capsule antigen conjugated to a protein carrier.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vi-TT TARGET Vi-TT International Vaccine Institute marketed Typhoid conjugate vaccine Salmonella typhi Vi polysaccharide antigen
Typhim Vi (Sanofi Pasteur MSD) Typhim Vi (Sanofi Pasteur MSD) Universitaire Ziekenhuizen KU Leuven marketed Inactivated bacterial vaccine Salmonella typhi Vi polysaccharide antigen
Control Vaccine Typbar TCV® Control Vaccine Typbar TCV® International Vaccine Institute phase 3 Conjugate vaccine Salmonella typhi Vi polysaccharide antigen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Typhoid conjugate vaccine class)

  1. International Vaccine Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vi-TT — Competitive Intelligence Brief. https://druglandscape.com/ci/vi-tt. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: